[Pre Diagnostics AS] is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis. With an estimated 75 million people having the d
FDA approval of Gen-Probe Inc. ’s Aptima cervical cancer screening test in late October may well mark a step-up in the continuing battle for share in the $300 million market for nucleic-acid-base